PMID- 29140109
OWN - NLM
STAT- MEDLINE
DCOM- 20180706
LR  - 20180706
IS  - 1931-8405 (Electronic)
IS  - 0889-2229 (Linking)
VI  - 33
IP  - S1
DP  - 2017 Nov
TI  - Host Methyltransferases and Demethylases: Potential New Epigenetic Targets for
      HIV Cure Strategies and Beyond.
PG  - S8-S22
LID - 10.1089/aid.2017.0180 [doi]
AB  - A successful HIV cure strategy may require reversing HIV latency to purge hidden 
      viral reservoirs or enhancing HIV latency to permanently silence HIV
      transcription. Epigenetic modifying agents show promise as antilatency
      therapeutics in vitro and ex vivo, but also affect other steps in the viral life 
      cycle. In this review, we summarize what we know about cellular DNA and protein
      methyltransferases (PMTs) as well as demethylases involved in HIV infection. We
      describe the biology and function of DNA methyltransferases, and their
      controversial role in HIV infection. We further explain the biology of PMTs and
      their effects on lysine and arginine methylation of histone and nonhistone
      proteins. We end with a focus on protein demethylases, their unique modes of
      action and their emerging influence on HIV infection. An outlook on the use of
      methylation-modifying agents in investigational HIV cure strategies is provided.
FAU - Boehm, Daniela
AU  - Boehm D
AD  - 1 Gladstone Institute of Virology and Immunology , San Francisco, California.
AD  - 2 Department of Medicine, University of California , San Francisco, California.
FAU - Ott, Melanie
AU  - Ott M
AD  - 1 Gladstone Institute of Virology and Immunology , San Francisco, California.
AD  - 2 Department of Medicine, University of California , San Francisco, California.
LA  - eng
GR  - P30 AI027763/AI/NIAID NIH HHS/United States
GR  - R01 DA043142/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
RN  - 0 (Anti-HIV Agents)
RN  - 9007-49-2 (DNA)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 2.1.1.- (DNA Modification Methylases)
RN  - EC 2.1.1.- (Protein Methyltransferases)
SB  - IM
SB  - X
MH  - Anti-HIV Agents/*pharmacology
MH  - DNA/metabolism
MH  - DNA Modification Methylases/*antagonists & inhibitors/genetics/metabolism
MH  - Epigenesis, Genetic/drug effects
MH  - HIV Infections/*drug therapy/virology
MH  - HIV-1/drug effects/genetics
MH  - Histone Demethylases/*antagonists & inhibitors/genetics/metabolism
MH  - Humans
MH  - Protein Methyltransferases/*antagonists & inhibitors/genetics/metabolism
MH  - Virus Activation/drug effects
MH  - Virus Latency/*drug effects
PMC - PMC5684665
OTO - NOTNLM
OT  - HIV cure
OT  - demethylase inhibitors
OT  - histone demethylase
OT  - latency reactivation
OT  - methyltransferase
OT  - methyltransferase inhibitors
EDAT- 2017/11/16 06:00
MHDA- 2018/07/07 06:00
CRDT- 2017/11/16 06:00
PMCR- 2018/11/01 00:00
PHST- 2018/11/01 00:00 [pmc-release]
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2018/07/07 06:00 [medline]
AID - 10.1089/aid.2017.0180 [doi]
PST - ppublish
SO  - AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S8-S22. doi: 10.1089/aid.2017.0180.